These results suggest that IL4Rα and IL13Rα1 might be involved in the progression of RCC through JAK2/FOXO3 pathway, and their expression might be used as the novel prognostic factor and promising therapeutic target for RCC patients. The gene discussed is JAK2; the disease is renal cell carcinoma.